Results 261 to 270 of about 5,838,181 (363)

Global, Population and Genetic Evidence on the Relationships Between Immune‐Mediated Inflammatory Disease and Cancer Risk

Cancer Innovation, Volume 5, Issue 1, February 2026.
Using a triangulation framework that synthesizes findings across global, population and genetic perspectives, this work comprehensively establishes associations between six immune‐mediated inflammatory diseases (IMIDs) and 33 cancers, identifying 170 statistically significant IMID‐cancer pairs, validating 20 in the UKBB cohort and uncovering a causal ...
Xuesi Dong, Jiaxin Xie, Zilin Luo, Hao Hong, Chenran Wang, Yadi Zheng, Xiaoyue Shi, Zeming Guo, Xiaolu Chen, Yongjie Xu, Wei Cao, Fei Wang, Dong Hang, Sipeng Shen, Fengwei Tan, Ni Li   +15 more
wiley   +1 more source

Kappa Light Chain-Restricted Multiple Myeloma with Biopsy-Proven Cast Nephropathy and Negative Bence-Jones Proteinuria: A Rare Clinical Presentation. [PDF]

Cureus
Gundala Raja H, Sivakumar M, Johal LK, Ali Khan S, Khan F.   +4 more
europepmc   +1 more source

Studies on human IgD myeloma proteins. Carbohydrate composition of intact proteins and some proteolytic fragments.

, 1975
R Jefferis, A J Butwell, JR Clamp
openalex   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma. [PDF]

Clin Exp Med
Wu Y, Zhang D, Jiang J, Zheng L, Zhou Z, Zhang Z, Nouri S.   +6 more
europepmc   +1 more source

Single‐Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer

Cancer Medicine, Volume 15, Issue 2, February 2026.
The figure shows single‐cell datasets of breast cancer collected from the GEO database, including estrogen receptor‐positive breast cancer, HER2‐positive breast cancer, and triple‐negative breast cancer. These datasets are used to analyze differences among breast cancer subtypes by studying the interactions among epithelial cells, fibroblasts ...
Yunlong Zhao, Xiaoyu Zhang, Yingying Wang, Xiaomin Yu, Fengchun Lv, Mingyu Gong, Xiu‐An Yang   +6 more
wiley   +1 more source

Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM.
Songdi Chen, Junqing Hu, Qian Zhang, Luling Mao, Qian Jiang, Chuyun Qian, Weize Zhang, Keting Jin, Jianhu Li, Ji‐nuo Wang, Yi Zhao   +10 more
wiley   +1 more source

Comparative analysis of three different serum-free light chain assays in the diagnosis of multiple myeloma. [PDF]

Ann Med
Cui F, Wang J, Chen X, Niu Y, Hu M, Liu F, Li H.   +6 more
europepmc   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source